
|Articles|February 16, 2021
Supplements and Featured Publications
- Current and Emerging Trends in Chronic Myeloid Leukemia
- Volume 1
- Issue 1
Current and Future Trends in Chronic Myeloid Leukemia
Advertisement
This publication includes a summary of data on therapeutic agents for the current and future treatment landscape of chronic myeloid leukemia. Hematologic oncology experts provide key insights on approaching disease management, including a discussion on treatment options through later-line settings.
Articles in this issue
about 5 years ago
Dr. Cortes on the Future of Ponatinib in CML Treatmentabout 5 years ago
Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CMLabout 5 years ago
Dr. Cortes on Navigating Among Frontline TKIs in the CML Paradigmabout 5 years ago
Dr. Jabbour on the ASCEMBL Data With Asciminib in Chronic-Phase CMLabout 5 years ago
Dr. Hobbs on Managing Ponatinib-Associated Toxicities in CMLabout 5 years ago
Dr. Sweet on Treatment Selection With TKIs in CMLAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































